Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1117-1122

  Hitre, E ^a   Budai, B ^a   Takacsi Nagy Z ^a   Rubovszky, G ^a   Toth E ^a   Remenar E ^a   Polgar C ^a   Lang I ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

cetuximab; adenoid cystic carcinoma; radiotherapy; chemotherapy

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL;

ADENOID CYSTIC CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RASH; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOID CYSTIC; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84883741316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.468     Document Type: Article

References (37)

1. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978-3984. (Pubitemid 47477277)
2. Alcedo JC, Fábrega JM, Arosemena JR, Urrutia A (2004) Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 26: 829-831. (Pubitemid 39159307)
3. Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA (2011) A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 117: 3374-3382.
4. Caballero M, Sosa EA, Tagliapietra A, Grau JJ (2013) Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone. Head Neck 35: E52-E54.
5. Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL (2012) A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23: 1562-1570.
6. De Dosso S, Mazzucchelli L, Ghielmini M, Saletti P (2009) Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori 95: 378-381.
7. Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol 45: 826-829.
8. Dubergé T, Bénézery K, Resbeut M, Azria D, Minsat M, Ellis S, Teissier E, Zaccariotto A, Champetier C, Cowen D (2012) Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases. Cancer Radiother 16: 247-256.
9. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23: 6271-6273, author reply 6273-6274.
10. Ghosal N, Mais K, Shenjere P, Julyan P, Hastings D, Ward T, Ryder WD, Bruce I, Homer J, Slevin NJ (2011) Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 49: 510-515.
11. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23(Suppl. Abstr): 5532.
12. Gomez DR, Hoppe BS, Wolden SL, Zhung JE, Patel SG, Kraus DH, Shah JP, Ghossein RA, Lee NY (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70: 1365-1372. (Pubitemid 351417750)
13. Guigay J, Bidault F, Temam S, Janot F, Raymond E, Faivre S (2007) Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. J Clin Oncol 25(Suppl. Abstr): 6086.
14. Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB (2006) Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 29: 153-157. (Pubitemid 44270955)
15. Hill ME, Constenla DO, A'Hern RP, Henk JM, Rhys-Evans P, Breach N, Archer D, Gore ME (1997) Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33: 275-278.
16. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23: 585-590. (Pubitemid 46224236)
17. Huang Y, Yu T, Fu X, Chen J, Liu Y, Xia Y, Zhang Z, Li L (2013) EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma. BMC Cell Biol 14: 13.
18. Jensen AD, Krauss J, Weichert W, Debus J, Münter MW (2010) RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol 5: 102.
19. Jensen AD, Nikoghosyan A, Hinke A, Debus J, Münter MW (2011) Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT (ACC, Erbituxs and particle therapy). BMC Cancer 11: 70.
20. Jia J, Zhang W, Liu JY, Chen G, Liu H, Zhong HY, Liu B, Cai Y, Zhang JL, Zhao YF (2013) Epithelial mesenchimal transition is required for aquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS One 7: e51549.
21. Ko YH, Lee MA, Hong YS, Lee KS, Jung CK, Kim YS, Sun DI, Kim BS, Kim MS, Kang JH (2007) Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin Oncol 37: 805-811. (Pubitemid 350258998)
22. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J (2010) Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated- accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 21: 2284-2289.
23. Laurie SA, Ho AL, Fury MG, Sherman E, Pfitser DG (2011) Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12: 815-824.
24. Le Tourneau C, Razak AR, Levy C, Calugaru V, Galatoire O, Dendale R, Desjardins L, Gan HK (2011) Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. Br J Ophthalmol 95: 1483-1489.
25. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL (2005) Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck 27: 1022-1027. (Pubitemid 41705578)
26. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L (2009a) Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 45: 986-990.
27. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L (2009b) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45: 574-578.
28. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC (2008) Salivary gland-type lung carcinomas. An EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21: 1168-1175.
29. Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, Gasco M, Lo Nigro C, Vitiello R, Violante S, Garrone O (2011) Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol 22: 712-717.
30. Ochel HJ, Gademann G, Rocken C, Wordehoff H (2005) Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res 25: 3659-3664. (Pubitemid 41105258)
31. Papaspyrou G, Hoch S, Rinaldo A, Rodrigo JP, Takes RP, van Herpen C, Werner JA, Ferlito A (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33: 905-911.
32. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43: 33-36. (Pubitemid 46162246)
33. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078. (Pubitemid 46638804)
34. Samant S, van den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI, Rasch C, Weber RS (2012) Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 34: 1263-1268.
35. Shen C, Xu T, Huang C, Hu C, He S (2012) Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol 48: 445-449.
36. Vered M, Braunstein E, Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24: 632-636. (Pubitemid 34734357)
37. Zwicker F, Roeder F, Thieke C, Timke C, Münter MW, Huber PE, Debus J (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187: 32-38.